COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · IEX Real-Time Price · USD
8.10
-0.15 (-1.82%)
At close: Apr 24, 2024, 4:00 PM
7.80
-0.30 (-3.70%)
After-hours: Apr 24, 2024, 6:54 PM EDT
Company Description
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States.
It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc
| Country | United Kingdom |
| IPO Date | Sep 18, 2020 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 186 |
| CEO | Kabir Kumar Nath M.A., M.B.A. |
Contact Details
Address: 3rd Floor, 1 Ashley Road, Altrincham Chesire, X0 WA14 2DT United Kingdom | |
| Phone | 1-716-676-6461 |
| Website | compasspathways.com |
Stock Details
| Ticker Symbol | CMPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001816590 |
| CUSIP Number | 20451W101 |
| ISIN Number | US20451W1018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kabir Nath M.A., M.B.A. | Chief Executive Officer and Director |
| Matthew Allen Owens | General Counsel and Chief Legal Officer |
| Dr. Guy Goodwin | Chief Medical Officer |
| Teri Loxam M.B.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Greg Ryslik Ph.D. | Chief Technology Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Christopher Williams | Chief Communications Officer |
| Anne Benedict | Chief People Officer |
| Lars Christian Wilde | Senior Advisor |
| Trevor Mill | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 8, 2024 | ARS | Filing |
| Apr 8, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 144 | Filing |
| Mar 13, 2024 | 144 | Filing |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |